By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...

The company is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent ...

Specialty Medicines drive strong sales as company maintains guidance and raises dividend GSK PLC (LSE:GSK, NYSE:GSK) reported ...

GSK posts higher profits but indicates sales growth to slow in 2026 - It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...

The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for ...

SALES FORECAST: The U.K. drugmaker is expected to post fourth-quarter sales of 8.495 billion pounds ($11.61 billion), according to consensus estimates provided by the company. GSK posted 8.12 billion ...

Its adjusted earnings per share rises to 25.5 pence, higher than analysts’ expectations Read more at The Business Times.

Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...

British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, ...

GSK's new CEO, Luke Miels, focuses on enhancing sales growth and accelerating drug development. Despite imminent patent ...

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled ...